Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Cash & Equivalents (2016 - 2025)

Lipocine (LPCN) has disclosed Cash & Equivalents for 13 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents changed N/A year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Sep 2025, changed N/A, and an annual FY2024 reading of $6.2 million, up 30.06% over the prior year.
  • Cash & Equivalents was $3.9 million for Q3 2025 at Lipocine, down from $6.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $45.8 million in Q4 2021 and bottomed at $2.4 million in Q3 2022.
  • Average Cash & Equivalents over 5 years is $12.0 million, with a median of $5.3 million recorded in 2022.
  • Peak annual rise in Cash & Equivalents hit 900.14% in 2023, while the deepest fall reached 85.12% in 2023.
  • Year by year, Cash & Equivalents stood at $45.8 million in 2021, then fell by 29.93% to $32.1 million in 2022, then crashed by 85.12% to $4.8 million in 2023, then surged by 30.06% to $6.2 million in 2024, then tumbled by 37.14% to $3.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for LPCN at $3.9 million in Q3 2025, $6.0 million in Q2 2025, and $3.4 million in Q1 2025.